Boston Scientific (BSX)
(Delayed Data from NYSE)
$87.59 USD
-1.18 (-1.33%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $87.59 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$87.59 USD
-1.18 (-1.33%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $87.59 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum C VGM
Zacks News
Is Labcorp Stock a Good Pick for Your Portfolio Right Now?
by Zacks Equity Research
Investors are increasingly optimistic about LH due to its partnerships and operational discipline.
Should You Retain Hologic Stock in Your Portfolio Now?
by Zacks Equity Research
HOLX's strength in the Molecular Diagnostics wing instills optimism among investors. Yet, macro woes and currency impacts raise concerns.
Competitive Pressure, Macroeconomic Woes Weigh on NEOG Stock
by Zacks Equity Research
NEOG faces intense competition resulting from competitors' development of new technologies, which could affect the marketability and profitability of its products.
MYGN Stock Might Gain From SneakPeek Availability in Retail Stores
by Zacks Equity Research
Myriad Genetics announces the availability of SneakPeek - the first at-home early fetal sex test in Walmart, Walgreens and CVS stores nationwide.
IART Stock to Gain From New Study Findings on DuraSeal Dural Sealant
by Zacks Equity Research
According to a health economic evaluation, Integra's DuraSeal Dural Sealant is revealed to reduce healthcare costs.
Top Analyst Reports for UnitedHealth, Bank of America & SAP
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Bank of America Corporation (BAC) and SAP SE (SAP).
QGEN Collaborates With McGill University Centre: Stock to Gain?
by Zacks Equity Research
QIAGEN joins forces with McGill University Centre for Microbiome Research to generate evidence-based knowledge for medicine and public health.
Expanding Global Market, NuVasive Benefits to Aid GMED Stock
by Zacks Equity Research
Globus Medical is seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.
Alcon Q3 Earnings Top Estimates, Margins Up, Stock Gains in Afterhours
by Zacks Equity Research
ALC's performance is driven by robust demand for the company's innovative products, balanced geographic footprint and strong execution by the team.
Labcorp Adds New Capabilities to Global Trial Connect: Stock to Gain?
by Zacks Equity Research
LH launches new enhancements to Global Trial Connect to streamline site workflow.
Is Quest Diagnostics Stock a Smart Addition to Your Portfolio Now?
by Zacks Equity Research
DGX exhibits strength in its base business. Increasing utilization of the Advanced Diagnostics offering is another positive.
National Vision Q3 Earnings Top Estimates, Revenues Lag, Stock Tumbles
by Zacks Equity Research
EYE's third-quarter 2024 results reflect ongoing strength in Managed Care, with growth in America's Best stores.
INGN Stock Gains Following Q3 Earnings Beat, Adjusted Gross Margin Up
by Zacks Equity Research
Inogen's overall third-quarter 2024 results continue to gain from higher business-to-business sales.
ZBH Stock to Gain Support From Market Share Gains Amid Macro Issues
by Zacks Equity Research
Zimmer Biomet expects ROSA and Persona Cementless Knee to enhance its robotics and cementless market penetration to 50% to 60% range at a rapid pace.
Haemonetics' Q2 Earnings and Revenues Top, Stock Up, Margins Expand
by Zacks Equity Research
HAE delivers impressive growth in the top and bottom lines in the second quarter of fiscal 2025.
OPK Stock Gains Following Q3 Earnings Beat, Gross Margin Contracts
by Zacks Equity Research
Lower revenues from OPKO Health's products and services dampen its overall third-quarter 2024 performance.
AMN Stock Falls Despite Q3 Earnings & Revenues Beat, Margins Contract
by Zacks Equity Research
AMN Healthcare's dismal results in the majority of its segments led to a soft overall third-quarter performance.
PBH Q2 Earnings Match Estimates, Revenues Beat, Shares Rise
by Zacks Equity Research
Prestige Consumer Healthcare's second-quarter sales are impacted by the ongoing supply chain challenges in the Clear Eyes business.
CLOV Stock Declines Despite Q3 Earnings Beat, FY24 View Revised
by Zacks Equity Research
Clover Health's third-quarter 2024 results continue to benefit from the strength of its business model.
Medtronic Stock Trading at a Discount Before Q2 Earnings: Time to Buy?
by Urmimala Biswas
Like its peers, the impact of the present geopolitical situation may have curbed fiscal second-quarter profits for Medtronic.
Veracyte Q3 Earnings Beat Estimates, 2024 Guidance Raised
by Zacks Equity Research
VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests.
BDX Stock Gains Following Q4 Earnings Beat and Higher Margins
by Zacks Equity Research
BD's overall topline in the fourth quarter of fiscal 2024 benefits from revenue growth in all segments.
QIAGEN Stock Flat Post Q3 Earnings & Revenue Beat, 2024 EPS View Up
by Zacks Equity Research
QGEN delivers another solid performance in the third quarter of 2024, with both the top and bottom lines surpassing estimates.
Phibro's Q1 Earnings Top Estimates, Stock Up, Net Sales Surge Y/Y
by Zacks Equity Research
PAHC delivers strong growth across all its segments in the first quarter of fiscal 2025.
Charles River's Q3 Earnings, Revenues Beat Estimates, Margins Fall
by Zacks Equity Research
CRL's organic revenue growth in the Manufacturing Solutions and RMS segments is more than offset by lower revenues in the DSA segment.